

Mild and Regioselective Azol-halogenation of Alkenes

Kai Sun,^{*,a} Baixue Luan,^a Zhenhua Liu,^b Jiali Zhu,^a Jikang Du,^a Enqi Bai,^a

Yu Fang,^a and Bing Zhang^c

^aCollege of Chemistry and Chemical Engineering, Anyang Normal University,
Anyang 455000, P. R. China

^bCollege of Chemistry, Shandong Normal University, Jinan 250014, P. R. China

^cCollege of Chemistry and Energy, Zhengzhou University, Zhengzhou 450001, P. R.
China

Corresponding author: sunk468@nenu.edu.cn

Supporting Information

Table of Contents

I. General remarks	S2
II. Synthesis procedure for compounds 3	S2
III. Analytical data of products obtained in this study.....	S3-12
IV. ¹ H and ¹³ C-NMR spectra for compounds 3 and 4.....	S4-S46

I. General remarks.

All reagents were purchased from commercial sources and used without further purification. ^1H NMR and ^{13}C NMR spectra were recorded on a Bruker Ascend™ 400 spectrometer in deuterated solvents containing TMS as an internal reference standard. High-resolution mass spectrometry (HRMS) analyses were conducted on a Waters LCT Premier/XE. Melting points were measured on a melting point apparatus equipped with a thermometer and were uncorrected. All the reactions were monitored by thin-layer chromatography (TLC) using GF254 silica gel-coated TLC plates. Purification by flash column chromatography was performed over SiO_2 (silica gel 200–300 mesh).

II. General procedure:

Styrene **1a** (0.45 mmol, 46.8 mg), 5-phenyl-1*H*-tetrazole **2a** (0.3 mmol, 43.8 mg) and NBS (0.6 mmol, 106.8 mg) were added to an open round-bottom flask. The mixture was stirred at rt. in DCE (2.0 mL) for about 12.0 h. Upon completion of the reaction (as monitored by TLC), the mixture was cooled to room temperature and quenched with water before being extracted with dichloromethane (5×3 mL). The combined organic layers were dried over anhydrous Na_2SO_4 and concentrated under reduced pressure to give a residue, which was purified by flash column chromatography over silica gel (EtOAc/petroleum ether = 1:5, v/v) to give compound **3a** (87.6 mg) in 89% yield.

III. Analytical data of products obtained in this study

1-(2-bromo-1-phenylethyl)-5-phenyl-1*H*-tetrazole (3a). White solid (89%, 87.6 mg), melting point: 96-97 °C; ¹H NMR (400 MHz; CDCl₃): δ = 4.02 (q, J = 5.2, 1H), 4.47 (t, J = 10.8, 1H), 6.22 (q, J = 4.8, 1H), 7.40-7.42 (m, 3H), 7.49-7.52 (m, 5H), 8.21 (dd, J_1 = 2.4, 1H, J_2 = 8.0, 2H). ¹³C NMR (100 MHz; CDCl₃): δ = 31.8, 69.4, 123.4, 124.3, 126.9, 127.0, 128.8, 129.2, 129.6, 130.4, 135.3, 145.4, 165.3. HRMS (ESI-TOF) Calcd for C₁₅H₁₄BrN₄, [M+H]⁺ 329.0404; Found 329.0409.

1-(2-bromo-1-(2-chlorophenyl)ethyl)-5-phenyl-1*H*-tetrazole (3b). Yellow oil liquid (84%, 91.6 mg), ¹H NMR (400 MHz; CDCl₃): δ = 4.04 (q, J = 4.4, 1H), 4.34 (d, J = 10.8, 1H), 6.81 (q, J = 4.4, 1H), 7.28-7.52 (m, 7H), 8.22 (t, J = 5.2, 2H). ¹³C NMR (100 MHz; CDCl₃): δ = 30.6, 65.6, 127.0, 127.1, 127.5, 127.7, 128.8, 130.2, 130.5, 130.6, 132.9, 133.1, 165.3. HRMS (ESI-TOF) Calcd for C₁₅H₁₃BrClN₄, [M+H]⁺ 363.0012; Found 363.0008.

1-(2-bromo-1-(3-chlorophenyl)ethyl)-5-phenyl-1*H*-tetrazole (3c). Yellow oil liquid (81%, 88.4 mg), ¹H NMR (400 MHz; CDCl₃): δ = 4.02 (q, J = 5.2, 1H), 4.42 (t, J = 10.8, 1H), 6.18 (q, J = 5.2, 1H), 7.38 (d, J = 4.8, 3H), 7.50-7.52 (m, 4H), 8.18-8.21 (m, 2H). ¹³C NMR (100 MHz; CDCl₃): δ = 31.4, 68.6, 125.3, 127.0, 127.1, 127.3, 128.9, 129.9, 130.5, 135.2, 137.0, 165.4. HRMS (ESI-TOF) Calcd for C₁₅H₁₃BrClN₄, [M+H]⁺ 363.0012; Found 363.0017.

1-(2-bromo-1-(3-bromophenyl)ethyl)-5-phenyl-1*H*-tetrazole (3d). White solid

(75%, 91.8 mg), melting point: 102-103 °C; ^1H NMR (400 MHz; CDCl_3): δ = 4.01 (q, J = 5.6, 1H), 4.41 (t, J = 10.6, 1H), 6.18 (q, J = 5.2, 1H), 7.29 (d, J = 8.0, 1H), 7.43-7.53 (m, 5H), 7.55 (d, J = 8.8, 1H), 8.20 (d, J = 6.8, 2H). ^{13}C NMR (100 MHz; CDCl_3): δ = 31.3, 68.6, 123.2, 125.7, 127.0, 128.9, 130.3, 130.5, 130.7, 132.8, 137.2, 165.4. HRMS (ESI-TOF) Calcd for $\text{C}_{15}\text{H}_{13}\text{Br}_2\text{N}_4$, $[\text{M}+\text{H}]^+$ 406.9508; Found 406.9501.

1-(2-bromo-1-(4-fluorophenyl)ethyl)-5-phenyl-1H-tetrazole (3e). Colourless liquid (89%, 92.6 mg), ^1H NMR (400 MHz; CDCl_3): δ = 4.05 (q, J = 4.8, 1H), 4.41 (t, J = 10.8, 1H), 6.61 (q, J = 5.2, 1H), 7.16-7.20 (m, 2H), 7.38-7.51 (m, 5H), 8.20 (d, J = 5.2, 2H). ^{13}C NMR (100 MHz; CDCl_3): δ = 30.8, 62.2, 116.0, 116.2, 122.6, 122.7, 124.9, 127.0, 127.1, 127.8, 127.9, 130.5, 131.3, 131.4, 138.4, 160.9, 165.3. HRMS (ESI-TOF) Calcd for $\text{C}_{15}\text{H}_{13}\text{BrFN}_4$, $[\text{M}+\text{H}]^+$ 347.0307; Found 347.0312.

1-(2-bromo-1-(4-chlorophenyl)ethyl)-5-phenyl-1H-tetrazole (3f). Yellow oil liquid (93%, 101.4 mg), ^1H NMR (400 MHz; CDCl_3): δ = 4.01 (q, J = 5.6, 1H), 4.41 (t, J = 10.8, 1H), 6.23 (q, J = 5.6, 1H), 7.38-7.51 (m, 7H), 8.19 (dd, J_1 = 3.6, 1H, J_2 = 8.0, 2H). ^{13}C NMR (100 MHz; CDCl_3): δ = 31.5, 68.6, 126.1, 126.8, 127.0, 127.1, 128.5, 128.8, 128.9, 129.5, 130.5, 133.6, 135.8, 165.4. HRMS (ESI-TOF) Calcd for $\text{C}_{15}\text{H}_{13}\text{BrClN}_4$, $[\text{M}+\text{H}]^+$ 363.0012; Found 363.0018.

1-(2-bromo-1-(4-nitrophenyl)ethyl)-5-phenyl-1H-tetrazole (3g). Yellow oil liquid (62%, 69.6 mg), ^1H NMR (400 MHz; CDCl_3): δ = 4.08 (q, J = 5.6, 1H), 4.41 (t, J = 10.6, 1H), 6.33 (m, 1H), 7.51 (dd, J_1 = 1.2, 1H, J_2 = 4.4, 3H), 7.70 (d, J = 8.8, 2H), 8.17 (dd, J_1 = 4.0, 1H, J_2 = 6.8, 2H), 8.27 (d, J = 8.8, 2H). ^{13}C NMR (100 MHz;

CDCl₃): δ = 30.8, 68.1, 123.8, 124.3, 126.8, 127.0, 127.1, 128.4, 128.9, 130.7, 141.5, 148.6, 165.7. HRMS (ESI-TOF) Calcd for C₁₅H₁₃BrN₅O₂, [M+H]⁺ 374.0252; Found 374.0258.

1-(2-bromo-1-(p-tolyl)ethyl)-5-phenyl-1H-tetrazole (3h). Yellow oil liquid (91%, 93.6 mg), ¹H NMR (400 MHz; CDCl₃): δ = 2.35 (s, 1H), 3.99 (q, J = 5.2, 1H), 4.46 (t, J = 10.8, 1H), 6.20 (q, J = 5.2, 1H), 7.20 (d, J = 6.8, 2H), 7.38 (d, J = 8.0, 2H), 7.48-7.51 (m, 3H), 8.19 (dd, J_1 = 2.4, 1H, J_2 = 8.0, 2H). ¹³C NMR (100 MHz; CDCl₃): δ = 21.1, 32.0, 69.3, 127.0, 127.3, 128.8, 129.7, 165.2. HRMS (ESI-TOF) Calcd for C₁₆H₁₆BrN₄, [M+H]⁺ 343.0558; Found 343.0561.

1-(2-bromo-1-(4-methoxyphenyl)ethyl)-5-phenyl-1H-tetrazole (3i). Yellow oil liquid (84%, 90.5 mg), ¹H NMR (400 MHz; CDCl₃): δ = 3.80 (s, 1H), 3.97 (q, J = 4.8, 1H), 4.44 (t, J = 10.8, 1H), 6.16 (q, J = 4.8, 1H), 6.91 (d, J = 8.8, 2H), 7.44-7.51 (m, 5H), 8.17 (d, J = 1.6, 2H). ¹³C NMR (100 MHz; CDCl₃): δ = 32.0, 55.3, 69.0, 114.5, 126.9, 127.3, 128.5, 128.8, 130.3, 160.5, 165.2. HRMS (ESI-TOF) Calcd for C₁₆H₁₆BrON₄, [M+H]⁺ 359.0508; Found 359.0514.

1-(2-bromo-1-(4-(tert-butyl)phenyl)ethyl)-5-phenyl-1H-tetrazole (3j). Yellow oil liquid (85%, 98.2 mg), ¹H NMR (400 MHz; CDCl₃): δ = 1.31 (s, 9H), 4.01 (q, J = 4.8, 1H), 4.49 (t, J = 10.8, 1H), 6.22 (q, J = 4.4, 1H), 7.41-7.52 (m, 7H), 8.22 (t, J = 7.6, 2H). ¹³C NMR (100 MHz; CDCl₃): δ = 31.2, 34.7, 69.3, 126.2, 126.8, 127.0, 127.3, 128.8, 130.4, 132.3, 152.8, 165.2. HRMS (ESI-TOF) Calcd for C₁₉H₂₂BrN₄, [M+H]⁺ 385.1030; Found 385.1025.

1-(2-bromo-1-(4-(chloromethyl)phenyl)ethyl)-5-phenyl-1*H*-tetrazole (3k).

Yellow oil liquid (77%, 87.2 mg), ¹H NMR (400 MHz; CDCl₃): δ = 3.99 (q, *J* = 5.2, 1H), 4.44 (t, *J* = 10.8, 1H), 4.56 (s, 1H), 6.22 (q, *J* = 5.2, 1H), 7.42-7.51 (m, 7H), 8.18 (dd, *J*₁ = 2.8, *J*₂ = 8.0, 2H). ¹³C NMR (100 MHz; CDCl₃): δ = 31.7, 45.3, 68.9, 127.0, 127.1, 127.5, 128.9, 129.4, 130.5, 135.3, 139.1, 165.3. HRMS (ESI-TOF) Calcd for C₁₆H₁₅BrClN₄, [M+H]⁺ 377.0171; Found 377.0176.

4-(2-bromo-1-(5-phenyl-1*H*-tetrazol-1-yl)ethyl)phenyl acetate (3l). White solid (80%, 92.9 mg), melting point: 108-109 °C; ¹H NMR (400 MHz; CDCl₃): δ = 2.30 (s, 1H), 3.98 (q, *J* = 4.8, 1H), 4.44 (t, *J* = 10.8, 1H), 6.21 (q, *J* = 4.8, 1H), 7.14 (d, *J* = 8.4, 2H), 7.49-7.55 (m, 5H), 8.18 (dd, *J*₁ = 2.4, *J*₂ = 7.8, 2H). ¹³C NMR (100 MHz; CDCl₃): δ = 21.0, 31.7, 68.8, 122.4, 127.0, 128.4, 128.8, 130.4, 132.7, 151.5, 165.3, 169.0. HRMS (ESI-TOF) Calcd for C₁₇H₁₆BrO₂N₄, [M+H]⁺ 387.0457; Found 387.0461.

1-(1-bromo-2-phenylpropan-2-yl)-5-phenyl-1*H*-tetrazole (3m). Yellow oil liquid (87%, 89.5 mg), ¹H NMR (400 MHz; CDCl₃): δ = 2.41 (s, 1H), 4.14 (d, *J* = 6.8, 1H), 4.66 (d, *J* = 6.8, 1H), 7.09 (dd, *J*₁ = 2.4, *J*₂ = 6.8, 2H), 7.34 (dd, *J*₁ = 3.2, *J*₂ = 6.0, 3H), 7.49 (dd, *J*₁ = 3.2, *J*₂ = 6.0, 3H), 8.21 (dd, *J*₁ = 2.4, *J*₂ = 7.8, 2H). ¹³C NMR (100 MHz; CDCl₃): δ = 25.4, 39.7, 70.5, 125.0, 125.8, 127.0, 127.4, 128.7, 128.8, 128.9, 130.3, 140.6, 164.9. HRMS (ESI-TOF) Calcd for C₁₆H₁₆BrN₄, [M+H]⁺ 343.0559; Found 343.0552.

1-(2-bromo-1,1-diphenylethyl)-5-phenyl-1*H*-tetrazole (3n). White solid (90%, 109.4 mg), melting point: 123-124 °C; ¹H NMR (400 MHz; CDCl₃): δ = 4.88 (s, 2H),

7.34-7.40 (m, 10H), 7.47-7.50 (m, 3H), 8.17 (dd, $J_1 = 2.0$, $J_2 = 7.6$, 2H). ^{13}C NMR (100 MHz; CDCl_3): $\delta = 38.5$, 76.4, 127.0, 127.3, 128.2, 128.5, 128.7, 128.8, 130.4, 139.3, 164.6. HRMS (ESI-TOF) Calcd for $\text{C}_{21}\text{H}_{18}\text{BrN}_4$, $[\text{M}+\text{H}]^+$ 405.0718; Found 405.0713.

1-(2-bromocyclooctyl)-5-phenyl-1H-tetrazole (3o). Yellow oil liquid (71%, 71.3 mg), ^1H NMR (400 MHz; CDCl_3): $\delta = 1.70$ -1.87 (m, 2H), 2.01-2.22 (m, 2H), 2.26-2.29 (m, 3H), 2.30-2.33 (m, 4H), 2.52-2.56 (m, 1H), 5.00-5.05 (m, 1H), 5.37-5.42 (m, 1H), 7.47-7.51 (m, 3H), 8.17 (dd, $J_1 = 2.0$, $J_2 = 8.0$, 2H). ^{13}C NMR (100 MHz; CDCl_3): $\delta = 24.6$, 25.0, 25.6, 25.7, 32.3, 32.9, 55.9, 71.0, 126.9, 127.5, 128.8, 130.2, 165.0. HRMS (ESI-TOF) Calcd for $\text{C}_{15}\text{H}_{20}\text{BrN}_4$, $[\text{M}+\text{H}]^+$ 335.0871; Found 335.0876.

1-(4-bromotetrahydrofuran-3-yl)-5-phenyl-1H-tetrazole (3p). Yellow oil liquid (76%, 67.3 mg), ^1H NMR (400 MHz; CDCl_3): $\delta = 1.70$ -1.87 (m, 2H), 2.01-2.22 (m, 2H), 2.26-2.29 (m, 3H), 2.30-2.33 (m, 4H), 2.52-2.56 (m, 1H), 5.00-5.05 (m, 1H), 5.37-5.42 (m, 1H), 7.47-7.51 (m, 3H), 8.17 (dd, $J_1 = 2.0$, $J_2 = 8.0$, 2H). ^{13}C NMR (100 MHz; CDCl_3): $\delta = 46.5$, 71.1, 71.2, 75.8, 126.8, 126.9, 128.9, 130.6, 165.6. HRMS (ESI-TOF) Calcd for $\text{C}_{11}\text{H}_{12}\text{BrON}_4$, $[\text{M}+\text{H}]^+$ 295.0195; Found 295.0198.

1-(2-iodo-1-phenylethyl)-5-phenyl-1H-tetrazole (3q). White solid (84%, 94.7 mg), melting point: 123-124 °C; ^1H NMR (400 MHz; CDCl_3): $\delta = 3.88$ (q, $J = 5.6$, 1H), 4.25 (t, $J = 10.6$, 1H), 6.17 (q, $J = 5.2$, 1H), 7.40 (t, $J = 5.2$, 3H), 7.49-7.51 (m, 5H), 8.19 (dd, $J_1 = 2.4$, 1H, $J_2 = 8.0$, 2H). ^{13}C NMR (100 MHz; CDCl_3): $\delta = 3.83$, 70.0, 126.9, 127.3, 128.8, 129.2, 129.5, 130.4, 136.1, 165.2. HRMS (ESI-TOF) Calcd for

C₁₅H₁₄N₄, [M+H]⁺ 377.0265; Found 377.0262.

1-(1-iodo-2-phenylpropan-2-yl)-5-phenyl-1*H*-tetrazole (3r). Yellow oil liquid (86%, 100.6 mg), ¹H NMR (400 MHz; CDCl₃): δ = 2.41 (s, 3H), 4.08 (d, *J* = 6.8, 1H), 4.49 (d, *J* = 6.8, 1H), 7.10 (dd, *J*₁ = 2.4, 1H, *J*₂ = 7.6, 2H), 7.33-7.52 (m, 6H), 8.23 (dd, *J*₁ = 1.6, 1H, *J*₂ = 8.0, 2H). ¹³C NMR (100 MHz; CDCl₃): δ = 14.9, 27.7, 69.9, 125.0, 127.0, 127.4, 128.6, 128.9, 129.0, 130.4, 140.3, 164.9. HRMS (ESI-TOF) Calcd for C₁₆H₁₆N₄, [M+H]⁺ 391.0420; Found 391.0426.

1-(1-iodo-3-phenylpropan-2-yl)-5-phenyl-1*H*-tetrazole (3s). Pink oil liquid (91%, 106.5 mg), ¹H NMR (400 MHz; CDCl₃): δ = 3.27-3.29 (m, 1H), 3.47 (t, *J* = 6.8, 1H), 3.71 (t, *J* = 8.4, 1H), 4.95-5.09 (m, 2H), 7.12 (d, *J* = 6.8, 1H), 7.24-7.35 (m, 4H), 7.51 (d, *J* = 5.6, 3H), 8.17 (s, 2H). ¹³C NMR (100 MHz; CDCl₃): δ = 27.7, 43.7, 67.1, 126.9, 127.4, 127.5, 128.7, 128.9, 129.0, 130.4, 130.5, 135.1, 137.8, 165.3. HRMS (ESI-TOF) Calcd for C₁₆H₁₆N₄, [M+H]⁺ 391.0420; Found 391.0427.

1-(1-iodopentan-2-yl)-5-phenyl-1*H*-tetrazole (3t). Yellow oil liquid (61%, 62.6 mg), ¹H NMR (400 MHz; CDCl₃): δ = 0.90-0.94 (m, 3H), 1.42-1.46 (m, 1H), 1.59-1.65 (m, 2H), 1.75-1.81 (m, 1H), 4.56-4.60 (m, 1H), 4.93-5.08 (m, 2H), 7.48 (dd, *J*₁ = 3.6, *J*₂ = 6.0, 3H), 8.16-8.18 (m, 2H). ¹³C NMR (100 MHz; CDCl₃): δ = 13.0, 22.4, 28.1, 38.7, 60.3, 126.9, 127.2, 128.9, 130.4, 165.2. HRMS (ESI-TOF) Calcd for C₁₂H₁₆N₄, [M+H]⁺ 343.0421; Found 343.0415.

1-(4-iodotetrahydrofuran-3-yl)-5-phenyl-1*H*-tetrazole (3u). Yellow oil liquid

(77%, 79.0 mg), ^1H NMR (400 MHz; CDCl_3): δ = 4.22 (q, J = 5.2, 1H), 4.36 (q, J = 6.4, 1H), 7.50 (q, J = 6.8, 1H), 4.60 (t, J = 10.4, 1H), 4.79 (t, J = 4.0, 1H), 5.67 (t, J = 3.2, 1H), 7.47-7.49 (m, 3H), 8.12 (q, J = 4.0, 1H). ^{13}C NMR (100 MHz; CDCl_3): δ = 18.8, 71.0, 72.7, 77.5, 126.9, 128.9, 130.6, 165.5. HRMS (ESI-TOF) Calcd for $\text{C}_{11}\text{H}_{12}\text{ION}_4$, $[\text{M}+\text{H}]^+$ 343.0057; Found 343.0053.

1-(3-iodobicyclo[2.2.1]heptan-2-yl)-5-phenyl-1H-tetrazole (3v). White solid (81%, 88.9 mg), melting point: 123-124 $^\circ\text{C}$; ^1H NMR (400 MHz; CDCl_3): δ = 1.49 (t, J = 6.8, 2H), 1.82-1.91 (m, 2H), 2.36 (t, J = 8.8, 1H), 2.62 (s, 1H), 3.39 (t, J = 6.8, 1H), 3.68 (d, J = 4.0, 1H), 3.85 (s, 1H), 4.57 (q, J = 4.8, 1H), 7.47 (t, J = 7.6, 3H), 8.18 (dd, J_1 = 1.6, J_2 = 8.0, 2H). ^{13}C NMR (100 MHz; CDCl_3): δ = 25.8, 26.4, 26.6, 36.2, 44.7, 47.9, 66.0, 126.8, 127.7, 128.8, 130.0, 164.4. HRMS (ESI-TOF) Calcd for $\text{C}_{14}\text{H}_{16}\text{IN}_4$, $[\text{M}+\text{H}]^+$ 367.0420; Found 367.0424.

1-(2-bromo-1-phenylethyl)-1H-benzo[d]imidazole (3w). White solid (80%, 72.0 mg), melting point: 35-36 $^\circ\text{C}$; ^1H NMR (400 MHz; CDCl_3): δ = 4.14-4.19 (m, 2H), 5.77 (t, J = 6.0, 1H), 7.25-7.30 (m, 5H), 7.37 (d, J = 4.4, 3H), 7.84 (d, J = 7.2, 1H), 8.20 (s, 1H). ^{13}C NMR (100 MHz; CDCl_3): δ = 31.8, 61.2, 110.2, 120.5, 122.7, 123.3, 126.6, 129.1, 129.3, 133.3, 136.4, 141.3, 143.5. HRMS (ESI-TOF) Calcd for $\text{C}_{15}\text{H}_{14}\text{BrN}_2$, $[\text{M}+\text{H}]^+$ 301.0340; Found 301.0345.

2-(2-bromo-1-phenylethyl)-2H-benzo[d][1,2,3]triazole (3x). White solid (42.6%, 38.5 mg), melting point: 103-104 $^\circ\text{C}$; ^1H NMR (400 MHz; CDCl_3): δ = 4.07 (q, J = 4.8, 1H), 4.62 (t, J = 10.4, 1H), 6.22 (q, J = 5.2, 1H), 7.36-7.42 (m, 5H), 7.50 (d, J = 6.0,

1H), 7.90 (dd, $J_1 = 3.2$, 1H, $J_2 = 6.8$, 2H). ^{13}C NMR (100 MHz; CDCl_3): $\delta = 32.6$, 72.1, 118.3, 126.6, 127.0, 129.0, 129.3, 136.5, 144.3. HRMS (ESI-TOF) Calcd for $\text{C}_{14}\text{H}_{13}\text{BrN}_3$, $[\text{M}+\text{H}]^+$ 302.0293; Found 302.0287.

1-(2-bromo-1-phenylethyl)-1*H*-benzo[*d*][1,2,3]triazole (3x'). White solid (28.4%, 25.6 mg), melting point: 133-134 °C; ^1H NMR (400 MHz; CDCl_3): $\delta = 4.15$ (q, $J = 5.2$, 1H), 4.64 (t, $J = 10.4$, 1H), 6.01 (q, $J = 5.6$, 1H), 7.34-7.43 (m, 8H), 8.08 (d, $J = 8.0$, 1H). ^{13}C NMR (100 MHz; CDCl_3): $\delta = 32.7$, 64.8, 109.3, 120.1, 124.2, 126.9, 127.6, 129.2, 133.1, 136.6, 146.0. HRMS (ESI-TOF) Calcd for $\text{C}_{14}\text{H}_{13}\text{BrN}_3$, $[\text{M}+\text{H}]^+$ 302.0293; Found 302.0289.

2-(2-bromo-1-phenylethyl)-5-methyl-2*H*-benzo[*d*][1,2,3]triazole (3y). White solid (48%, 45.5 mg), melting point: 79-80 °C; ^1H NMR (400 MHz; CDCl_3): $\delta = 2.50$ (s, 3H), 4.05 (q, $J = 5.2$, 1H), 4.60 (t, $J = 10.8$, 1H), 6.19 (q, $J = 4.8$, 1H), 7.23 (d, $J = 8.8$, 1H), 7.35 (d, $J = 6.8$, 3H), 7.48 (dd, $J_1 = 1.6$, $J_2 = 7.6$, 2H), 7.65 (s, 1H), 7.78 (d, $J = 8.8$, 1H). ^{13}C NMR (100 MHz; CDCl_3): $\delta = 22.0$, 32.7, 71.9, 116.5, 117.7, 127.0, 129.0, 129.2, 129.5, 136.6, 136.7, 143.0, 144.8. HRMS (ESI-TOF) Calcd for $\text{C}_{15}\text{H}_{15}\text{BrN}_3$, $[\text{M}+\text{H}]^+$ 316.0449; Found 316.0455.

2-(2-bromo-1-phenylethyl)-5-methyl-2*H*-benzo[*d*][1,2,3]triazole (3y'). Yellow oil liquid (32%, 37.9 mg), ^1H NMR (400 MHz; CDCl_3): $\delta = 2.48$ (s, 3H), 4.13-4.18 (m, 1H), 4.62-4.68 (m, 1H), 5.97-6.02 (m, 1H), 7.20 (s, 1H), 7.29-7.39 (m, 7H), 7.41 (d, $J = 5.2$, 1H). ^{13}C NMR (100 MHz; CDCl_3): $\delta = 21.4$, 32.7, 64.8, 108.4, 108.8, 119.0, 119.5, 126.9, 129.1, 129.7, 134.2, 136.7, 146.6. HRMS (ESI-TOF) Calcd for

C₁₅H₁₅BrN₃, [M+H]⁺ 316.0449; Found 316.0452.

1-(2-bromo-1-phenylethyl)-5-chloro-1*H*-benzo[*d*][1,2,3]triazole (3z). Yellow oil liquid (48.1%, 48.5 mg), ¹H NMR (400 MHz; CDCl₃): δ = 4.01 (q, *J* = 4.8, 1H), 4.47 (t, *J* = 10.4, 1H), 6.24 (q, *J* = 4.8, 1H), 7.38-7.43 (m, 5H), 7.49 (dd, *J*₁ = 2.0, *J*₂ = 7.6, 2H), 8.09 (d, *J* = 6.8, 1H), 8.21 (s, 1H). ¹³C NMR (100 MHz; CDCl₃): δ = 31.9, 69.6, 125.0, 127.0, 127.1, 129.0, 129.3, 129.8, 130.2, 130.4, 134.9, 135.1, 164.1. HRMS (ESI-TOF) Calcd for C₁₄H₁₂BrClN₃, [M+H]⁺ 335.9905; Found 335.9909.

1-(2-bromo-1-phenylethyl)-5-chloro-1*H*-benzo[*d*][1,2,3]triazole (z'). Yellow oil liquid (28.9%, 29.1 mg), ¹H NMR (400 MHz; CDCl₃): δ = 4.12-4.17 (m, 1H), 4.65 (t, *J* = 10.4, 1H), 5.92-5.97 (m, 1H), 7.35-7.43 (m, 7H), 8.02 (d, *J* = 8.8, 1H). ¹³C NMR (100 MHz; CDCl₃): δ = 32.5, 65.1, 109.1, 110.2, 119.5, 121.1, 125.4, 126.9, 128.6, 129.3, 134.2, 136.2, 146.5. HRMS (ESI-TOF) Calcd for C₁₄H₁₂BrClN₃, [M+H]⁺ 335.9905; Found 335.9901.

2-(2-bromo-1-phenylethyl)benzo[*d*]isothiazol-3(2*H*)-one 1,1-dioxide (3aa). White solid (81%, 135.6 mg), melting point: 113-114 °C; ¹H NMR (400 MHz; CDCl₃): δ = 4.12 (q, *J* = 7.2, 1H), 4.52 (q, *J* = 9.2, 1H), 5.45 (q, *J* = 7.2, 1H), 7.38 (q, *J* = 6.8, 3H), 7.61 (d, *J* = 6.8, 2H), 7.80-7.87 (m, 3H), 8.03 (d, *J* = 7.2, 1H). ¹³C NMR (100 MHz; CDCl₃): δ = 29.8, 58.4, 120.9, 125.3, 126.9, 128.4, 128.8, 129.2, 134.4, 134.9, 135.2, 137.3, 158.7. HRMS (ESI-TOF) Calcd for C₁₅H₁₃BrSNO₃, [M+H]⁺ 365.9801; Found 365.9805.


***N*-(2-bromo-1-phenylethyl)-*N*-(phenylsulfonyl)benzenesulfonamide (3ab).**

White solid (96%, 138.2 mg), melting point: 153-155 °C; ¹H NMR (400 MHz; CDCl₃): δ = 3.31 (q, *J* = 3.6, 1H), 4.46 (t, *J* = 10.8, 1H), 5.79 (q, *J* = 3.2, 1H), 7.32-7.60 (m, 15H). ¹³C NMR (100 MHz; CDCl₃): δ = 29.8, 64.5, 128.1, 128.4, 128.6, 128.9, 129.6, 132.6, 133.9, 139.8. HRMS (ESI-TOF) Calcd for C₂₀H₁₉BrS₂NO₄, [M+H]⁺ 479.9940; Found 479.9936.



5-phenyl-1-(1-phenylvinyl)-1*H*-tetrazole (4). White solid, melting point: 164-165 °C; ¹H NMR (400 MHz; CDCl₃): δ = 5.70 (s, 1H), 6.12 (d, *J* = 0.8, 1H), 7.45-7.52 (m, 8H), 8.21 (q, *J* = 4.0, 1H). ¹³C NMR (100 MHz; CDCl₃): δ = 110.9, 127.1, 127.8, 128.5, 128.9, 129.8, 130.5, 133.3, 143.6, 164.9.

IV. ¹H and ¹³C-NMR spectra for compounds 3 and 4



Compound 3a





Compound 3b





Compound 3c





Compound 3d





Compound 3e





Compound 3f




Compound 3g




Compound 3h




Compound 3i




Compound 3j





Compound 3k




Compound 3l




Compound 3m




Compound 3n




Compound 3o




9991+@skk-20190301-lbx-huanxinxi-COSY 1 1 D:\data\skk




9991+@skk-20190301-lbx-huanxinxi-COSY 1 1 D:\data\skk





Compound 3p





Compound 3q




Compound 3r




Compound 3s




Compound 3t





Compound 3u





Compound 3v









Compound 3w





Compound 3x





Compound 3x'




Compound 3y




Compound 3y'





Compound 3z





Compound 3z'



Compound 3aa



Compound 3ab



Compound 4

